BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its first quarter 2013 financial results on Tuesday, May 7, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Tuesday, May 7, 2013
1:30 p.m. Pacific Time / 4:30
p.m. Eastern Time
- Telephone (877) 941-0843 (domestic) or (480) 629-9866 (international); conference ID 4614604
- Webcast available at http://www.seattlegenetics.com/ in the Investors and News section
REPLAY access
- Telephone replay will be available beginning at approximately 3:30 p.m. PT on Tuesday, May 7, 2013 through 5:00 p.m. PT on Thursday, May 9, 2013 by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4614604
- Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com/ in the Investors and News section
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company’s lead program, ADCETRIS® (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional marketing authorization from the European Commission in October 2012. Seattle Genetics also has four other clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at www.seattlegenetics.com.
